Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 19574224
Zhong D, et al. (2009) The Glycolytic Inhibitor 2-Deoxyglucose Activates Multiple Prosurvival Pathways through IGF1R. J Biol Chem 284, 23225-33 19574224
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S58-p - 14-3-3 zeta (human)
Modsite: VVGARRssWRVVssI SwissProt Entrez-Gene
Orthologous residues
14‑3‑3 zeta (human): S58‑p, 14‑3‑3 zeta (mouse): S58‑p, 14‑3‑3 zeta (rat): S58‑p, 14‑3‑3 zeta (sheep): S58‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

T37-p - 4E-BP1 (human)
Modsite: PPGDysttPGGtLFs SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): T37‑p, 4E‑BP1 (mouse): T36‑p, 4E‑BP1 (rat): T36‑p, 4E‑BP1 (fruit fly): T37‑p, 4E‑BP1 (cow): T37‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), Calu-1 (squamous), NCI-H1299 (pulmonary), NCI-H157 (pulmonary), NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase
erlotinib 2-deoxyglucose no effect upon treatment-induced increase
erlotinib no change compared to control
IGF1R_inhibitor_II 2-deoxyglucose inhibit treatment-induced increase
IGF1R_inhibitor_II no change compared to control
siRNA 2-deoxyglucose inhibit treatment-induced increase siRNA IGF1R
anti-IGF1R 2-deoxyglucose inhibit treatment-induced increase
IGF-1 increase
IGF-1 IGFBP3 (human) inhibit treatment-induced increase
IGFBP3 (human) no change compared to control
2-deoxyglucose IGFBP3 (human) inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced
Effect of modification (process):  cell growth, altered

T183-p - AMPKA1 (human)
Modsite: sDGEFLRtsCGsPNy SwissProt Entrez-Gene
Orthologous residues
AMPKA1 (human): T183‑p, AMPKA1 iso2 (human): T198‑p, AMPKA1 (mouse): T183‑p, AMPKA1 (rat): T183‑p, AMPKA1 (fruit fly): T184‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S75-p - BAD (human)
Modsite: EIRsRHssyPAGtED SwissProt Entrez-Gene
Orthologous residues
BAD (human): S75‑p, BAD (mouse): S112‑p, BAD (rat): S113‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S99-p - BAD (human)
Modsite: PFrGrsRsAPPNLWA SwissProt Entrez-Gene
Orthologous residues
BAD (human): S99‑p, BAD (mouse): S136‑p, BAD (rat): S137‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S62-p - Bcl-xL (human)
Modsite: PSWHLADsPAVNGAT SwissProt Entrez-Gene
Orthologous residues
Bcl‑xL (human): S62‑p, Bcl‑xL (mouse): S62‑p, Bcl‑xL (rat): S62‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S1524-p - BRCA1 (human)
Modsite: LQNRNYPsQEELIKV SwissProt Entrez-Gene
Orthologous residues
BRCA1 (human): S1524‑p, BRCA1 iso6 (human): S420‑p, BRCA1 iso7 (human): S1545‑p, BRCA1 (mouse): S1481‑p, BRCA1 (rat): S1482‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

T286-p - CAMK2A (human)
Modsite: SCMHRQEtVDCLKKF SwissProt Entrez-Gene
Orthologous residues
CAMK2A (human): T286‑p, CAMK2A iso2 (human): T286‑p, CAMK2A (mouse): T286‑p, CAMK2A iso2 (mouse): , CAMK2A (rat): T286‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

Y14-p - caveolin-1 (human)
Modsite: VDsEGHLytVPIREQ SwissProt Entrez-Gene
Orthologous residues
caveolin‑1 (human): Y14‑p, caveolin‑1 iso2 (human): , caveolin‑1 (mouse): Y14‑p, caveolin‑1 (rat): Y14‑p, caveolin‑1 (dog): Y14‑p, caveolin‑1 (sheep): Y14‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

Y15-p - CDK1 (human)
Modsite: EkIGEGtyGVVykGR SwissProt Entrez-Gene
Orthologous residues
CDK1 (human): Y15‑p, CDK1 iso2 (human): Y15‑p, CDK1 (mouse): Y15‑p, CDK1 (rat): Y15‑p, CDK1 (chicken): Y15‑p, CDK1 (fruit fly): Y15‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S280-p - Chk1 (human)
Modsite: AKRPRVtsGGVsEsP SwissProt Entrez-Gene
Orthologous residues
Chk1 (human): S280‑p, Chk1 (mouse): S280‑p, Chk1 (rat): S280‑p, Chk1 (chicken): S280‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S317-p - Chk1 (human)
Modsite: ENVkYsssQPEPRTG SwissProt Entrez-Gene
Orthologous residues
Chk1 (human): S317‑p, Chk1 (mouse): S317‑p, Chk1 (rat): S317‑p, Chk1 (chicken): S317‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S516-p - Chk2 (human)
Modsite: PQVLAQPstSRKRPR SwissProt Entrez-Gene
Orthologous residues
Chk2 (human): S516‑p, Chk2 iso9 (human): S559‑p, Chk2 iso11 (human): S198‑p, Chk2 iso12 (human): S487‑p, Chk2 (mouse): S520‑p, Chk2 (rat): S519‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S133-p - CREB (human)
Modsite: EILsRRPsyRkILND SwissProt Entrez-Gene
Orthologous residues
CREB (human): S133‑p, CREB iso2 (human): S119‑p, CREB (mouse): S133‑p, CREB (rat): S133‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S366-p - EEF2K (human)
Modsite: sPQVRtLsGSRPPLL SwissProt Entrez-Gene
Orthologous residues
EEF2K (human): S366‑p, EEF2K (mouse): S365‑p, EEF2K (rat): S365‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

Y1110-p - EGFR (human)
Modsite: GsVQNPVyHNQPLNP SwissProt Entrez-Gene
Orthologous residues
EGFR (human): Y1110‑p, EGFR iso2 (human): , EGFR iso5 (human): , EGFR (mouse): Y1110‑p, EGFR (rat): Y1109‑p, EGFR (pig): Y1109‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S52-p - eIF2-alpha (human)
Modsite: MILLsELsRRRIRsI SwissProt Entrez-Gene
Orthologous residues
eIF2‑alpha (human): S52‑p, eIF2‑alpha (mouse): S52‑p, eIF2‑alpha (rat): S52‑p, eIF2‑alpha (rabbit): S51‑p, eIF2‑alpha (fruit fly): S51‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S383-p - ELK1 (human)
Modsite: IHFWSTLsPIAPRsP SwissProt Entrez-Gene
Orthologous residues
ELK1 (human): S383‑p, ELK1 (mouse): S384‑p, ELK1 (rat): S382‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S167-p - ER-alpha (human)
Modsite: GGRERLAsTNDkGSM SwissProt Entrez-Gene
Orthologous residues
ER‑alpha (human): S167‑p, ER‑alpha (mouse): S171‑p, ER‑alpha (rat): S172‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), MDA-MB-435 (breast cell), NCI-H1299 (pulmonary), NCI-H157 (pulmonary), NCI-H1792 (pulmonary), NCI-H23 (pulmonary), NCI-H358 (pulmonary), NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase
U0126 2-deoxyglucose inhibit treatment-induced increase
PD98059 2-deoxyglucose inhibit treatment-induced increase
anti-IGF1R 2-deoxyglucose inhibit treatment-induced increase
IGF1R_inhibitor_II 2-deoxyglucose inhibit treatment-induced increase
erlotinib 2-deoxyglucose no effect upon treatment-induced increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), MDA-MB-435 (breast cell), NCI-H1299 (pulmonary), NCI-H157 (pulmonary), NCI-H1792 (pulmonary), NCI-H23 (pulmonary), NCI-H358 (pulmonary), NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase
U0126 2-deoxyglucose inhibit treatment-induced increase
PD98059 2-deoxyglucose inhibit treatment-induced increase
anti-IGF1R 2-deoxyglucose inhibit treatment-induced increase
IGF1R_inhibitor_II 2-deoxyglucose inhibit treatment-induced increase
erlotinib 2-deoxyglucose no effect upon treatment-induced increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), MDA-MB-435 (breast cell), NCI-H1299 (pulmonary), NCI-H157 (pulmonary), NCI-H1792 (pulmonary), NCI-H23 (pulmonary), NCI-H358 (pulmonary), NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase
U0126 2-deoxyglucose inhibit treatment-induced increase
PD98059 2-deoxyglucose inhibit treatment-induced increase
anti-IGF1R 2-deoxyglucose inhibit treatment-induced increase
IGF1R_inhibitor_II 2-deoxyglucose inhibit treatment-induced increase
erlotinib 2-deoxyglucose no effect upon treatment-induced increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), MDA-MB-435 (breast cell), NCI-H1299 (pulmonary), NCI-H157 (pulmonary), NCI-H1792 (pulmonary), NCI-H23 (pulmonary), NCI-H358 (pulmonary), NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase
U0126 2-deoxyglucose inhibit treatment-induced increase
PD98059 2-deoxyglucose inhibit treatment-induced increase
anti-IGF1R 2-deoxyglucose inhibit treatment-induced increase
IGF1R_inhibitor_II 2-deoxyglucose inhibit treatment-induced increase
erlotinib 2-deoxyglucose no effect upon treatment-induced increase

S256-p - FOXO1A (human)
Modsite: sPrRrAAsMDNNskF SwissProt Entrez-Gene
Orthologous residues
FOXO1A (human): S256‑p, FOXO1A (mouse): S253‑p, FOXO1A (rat): S250‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S21-p - GSK3A (human)
Modsite: sGrARtssFAEPGGG SwissProt Entrez-Gene
Orthologous residues
GSK3A (human): S21‑p, GSK3A (mouse): S21‑p, GSK3A (rat): S21‑p, GSK3A (cow): S21‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S9-p - GSK3B (human)
Modsite: SGRPRttsFAEsCkP SwissProt Entrez-Gene
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S9‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

Y877-p - HER2 (human)
Modsite: LDIDEtEyHADGGkV SwissProt Entrez-Gene
Orthologous residues
HER2 (human): Y877‑p, HER2 iso2 (human): Y267‑p, HER2 iso5 (human): Y847‑p, HER2 (mouse): Y878‑p, HER2 (rat): Y879‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

Y512-p - ICAM1 (human)
Modsite: RQRKIKKyRLQQAQk SwissProt Entrez-Gene
Orthologous residues
ICAM1 (human): Y512‑p, ICAM1 (mouse): Y518‑p, ICAM1 (rat): Y526‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

Y1161-p - IGF1R (human)
Modsite: FGMTRDIyEtDyyRk SwissProt Entrez-Gene
Orthologous residues
IGF1R (human): Y1161‑p, IGF1R (mouse): Y1163‑p, IGF1R (rat): Y1162‑p, IGF1R (pig): Y1161‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S161-p - IkB-epsilon (human)
Modsite: QyDsGIEsLRsLRsL SwissProt Entrez-Gene
Orthologous residues
IkB‑epsilon (human): S161‑p, IkB‑epsilon iso3 (human): S84‑p, IkB‑epsilon (mouse): S22‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

Y773-p - ITGB3 (human)
Modsite: DtANNPLyKEAtstF SwissProt Entrez-Gene
Orthologous residues
ITGB3 (human): Y773‑p, ITGB3 (mouse): Y772‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

Y785-p - ITGB3 (human)
Modsite: stFTNItyRGT____ SwissProt Entrez-Gene
Orthologous residues
ITGB3 (human): Y785‑p, ITGB3 (mouse): Y784‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

Y1034-p - JAK1 (human)
Modsite: AIEtDkEyytVkDDR SwissProt Entrez-Gene
Orthologous residues
JAK1 (human): Y1034‑p, JAK1 (mouse): Y1033‑p, JAK1 (rat): Y1078‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

Y221-p - JAK2 (human)
Modsite: IRAKIQDyHILTRKR SwissProt Entrez-Gene
Orthologous residues
JAK2 (human): Y221‑p, JAK2 (mouse): Y221‑p, JAK2 (rat): Y221‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

Y1007-p - JAK2 (human)
Modsite: VLPQDKEyyKVkEPG SwissProt Entrez-Gene
Orthologous residues
JAK2 (human): Y1007‑p, JAK2 (mouse): Y1007‑p, JAK2 (rat): Y1007‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S243-p - Jun (human)
Modsite: PGEtPPLsPIDMEsQ SwissProt Entrez-Gene
Orthologous residues
Jun (human): S243‑p, Jun (mouse): S246‑p, Jun (rat): S246‑p, Jun (cow): S247‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S79-p - JunB (human)
Modsite: QGSDTGAsLKLASSE SwissProt Entrez-Gene
Orthologous residues
JunB (human): S79‑p, JunB (mouse): S79‑p, JunB (rat): S79‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S259-p - JunB (human)
Modsite: RDAtPPVsPINMEDQ SwissProt Entrez-Gene
Orthologous residues
JunB (human): S259‑p, JunB (mouse): S256‑p, JunB (rat): S256‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S255-p - JunD (human)
Modsite: DVPsFGEsPPLsPID SwissProt Entrez-Gene
Orthologous residues
JunD (human): S255‑p, JunD (mouse): S249‑p, JunD (rat): S249‑p, JunD (cow): S255‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

Y721-p - Kit (human)
Modsite: CSDStNEyMDMKPGV SwissProt Entrez-Gene
Orthologous residues
Kit (human): Y721‑p, Kit (mouse): Y723‑p, Kit (rat): Y722‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

T292-p - MEK1 (human)
Modsite: EtPPRPRtPGRPLss SwissProt Entrez-Gene
Orthologous residues
MEK1 (human): T292‑p, MEK1 iso2 (human): T266‑p, MEK1 (mouse): T292‑p, MEK1 (rat): T292‑p, MEK1 (rabbit): T292‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

T394-p - MEK2 (human)
Modsite: LRLNQPGtPtRtAV_ SwissProt Entrez-Gene
Orthologous residues
MEK2 (human): T394‑p, MEK2 (mouse): T395‑p, MEK2 (rat): T394‑p, MEK2 (chicken): T392‑p, MEK2 (cow): T394‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S218-p - MKK3 (human)
Modsite: IsGyLVDsVAKtMDA SwissProt Entrez-Gene
Orthologous residues
MKK3 (human): S218‑p, MKK3 iso2 (human): S189‑p, MKK3 iso3 (human): S223‑p, MKK3 (mouse): S218‑p, MKK3 (rat): S290‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

T58-p - Myc (human)
Modsite: kkFELLPtPPLsPsR SwissProt Entrez-Gene
Orthologous residues
Myc (human): T58‑p, Myc iso2 (human): T73‑p, Myc (mouse): T58‑p, Myc (rat): T58‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S373-p - Myc (human)
Modsite: RRNELkRsFFALRDQ SwissProt Entrez-Gene
Orthologous residues
Myc (human): S373‑p, Myc iso2 (human): S388‑p, Myc (mouse): S373‑p, Myc (rat): S373‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S893-p - NFkB-p105 (human)
Modsite: EVIQAAssPVKtTsQ SwissProt Entrez-Gene
Orthologous residues
NFkB‑p105 (human): S893‑p, NFkB‑p105 iso2 (human): S894‑p, NFkB‑p105 (mouse): S897‑p, NFkB‑p105 (rat): S898‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S529-p - NFkB-p65 (human)
Modsite: GLPNGLLsGDEDFSs SwissProt Entrez-Gene
Orthologous residues
NFkB‑p65 (human): S529‑p, NFkB‑p65 (mouse): S527‑p, NFkB‑p65 (rat): S528‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

Y182-p - P38A (human)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S6-p - p53 (human)
Modsite: __MEEPQsDPsVEPP SwissProt Entrez-Gene
Orthologous residues
p53 (human): S6‑p, p53 iso2 (human): S6‑p, p53 iso4 (human): , p53 (mouse): S9‑p, p53 iso2 (mouse): S9‑p, p53 (rat): S6‑p, p53 (rabbit): S6‑p, p53 (green monkey): S6‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S315-p - p53 (human)
Modsite: LPNNtsssPQPkkkP SwissProt Entrez-Gene
Orthologous residues
p53 (human): S315‑p, p53 iso2 (human): S315‑p, p53 iso4 (human): S276‑p, p53 (mouse): S312‑p, p53 iso2 (mouse): S312‑p, p53 (rat): S313‑p, p53 (rabbit): S313‑p, p53 (green monkey): S315‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S447-p - p70S6K (human)
Modsite: GsPRtPVsPVkFsPG SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): S447‑p, p70S6K iso2 (human): S424‑p, p70S6K (mouse): S447‑p, p70S6K (rat): S447‑p, p70S6K iso2 (rat): S424‑p, p70S6K (fruit fly): S430‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S241-p - PDK1 (human)
Modsite: skQARANsFVGtAQy SwissProt Entrez-Gene
Orthologous residues
PDK1 (human): S241‑p, PDK1 iso2 (human): S191‑p, PDK1 iso4 (human): S114‑p, PDK1 iso5 (human): S241‑p, PDK1 (mouse): S244‑p, PDK1 (rat): S244‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

Y402-p - Pyk2 (human)
Modsite: CsIEsDIyAEIPDEt SwissProt Entrez-Gene
Orthologous residues
Pyk2 (human): Y402‑p, Pyk2 iso2 (human): Y402‑p, Pyk2 (mouse): Y402‑p, Pyk2 (rat): Y402‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S71-p - RAC1 (human)
Modsite: yDRLRPLsYPQTDVF SwissProt Entrez-Gene
Orthologous residues
RAC1 (human): S71‑p, RAC1 iso2 (human): S71‑p, RAC1 (mouse): S71‑p, RAC1 (rat): S71‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S780-p - Rb (human)
Modsite: strPPtLsPIPHIPr SwissProt Entrez-Gene
Orthologous residues
Rb (human): S780‑p, Rb (mouse): S773‑p, Rb (rat): S772‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

Y349-p - SHC1 (human)
Modsite: EEPPDHQyyNDFPGK SwissProt Entrez-Gene
Orthologous residues
SHC1 (human): Y349‑p, SHC1 iso2 (human): Y239‑p, SHC1 iso3 (human): Y194‑p, SHC1 iso6 (human): Y349‑p, SHC1 iso7 (human): Y239‑p, SHC1 (mouse): Y349‑p, SHC1 iso2 (mouse): Y239‑p, SHC1 iso3 (mouse): Y194‑p, SHC1 (rat): Y349‑p, SHC1 iso2 (rat): Y239‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S576-p - SHP-2 (human)
Modsite: CAEMREDsARVyENV SwissProt Entrez-Gene
Orthologous residues
SHP‑2 (human): S576‑p, SHP‑2 iso1 (human): S580‑p, SHP‑2 (mouse): S576‑p, SHP‑2 (rat): S580‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

Y419-p - Src (human)
Modsite: RLIEDNEytARQGAk SwissProt Entrez-Gene
Orthologous residues
Src (human): Y419‑p, Src iso2 (human): Y425‑p, Src (mouse): Y424‑p, Src iso2 (mouse): Y418‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

Y701-p - STAT1 (human)
Modsite: DGPkGtGyIktELIs SwissProt Entrez-Gene
Orthologous residues
STAT1 (human): Y701‑p, STAT1 iso2 (human): Y701‑p, STAT1 (mouse): Y701‑p, STAT1 (rat): Y701‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

Y694-p - STAT5A (human)
Modsite: LAkAVDGyVkPQIkQ SwissProt Entrez-Gene
Orthologous residues
STAT5A (human): Y694‑p, STAT5A (mouse): Y694‑p, STAT5A iso2 (mouse): , STAT5A (rat): Y694‑p, STAT5A (fruit fly): Y711‑p, STAT5A (sheep): Y694‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

S404-p - Tau iso8 (human)
Modsite: PVVsGDtsPRHLsNV SwissProt Entrez-Gene
Orthologous residues
Tau (human): S721‑p, Tau iso2 (human): S315‑p, Tau iso3 (human): S279‑p, Tau iso4 (human): S344‑p, Tau iso5 (human): S373‑p, Tau iso6 (human): S346‑p, Tau iso7 (human): S375‑p, Tau iso8 (human): S404‑p, Tau (mouse): S696‑p, Tau iso3 (mouse): S393‑p, Tau iso7 (mouse): S353‑p, Tau (rat): S715‑p, Tau (cow): S411‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

Y516-p - TrkB (human)
Modsite: PVIENPQyFGITNSQ SwissProt Entrez-Gene
Orthologous residues
TrkB (human): Y516‑p, TrkB iso4 (human): Y532‑p, TrkB (mouse): Y515‑p, TrkB iso2 (mouse): , TrkB (rat): Y515‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

Y1054-p - Tyk2 (human)
Modsite: AVPEGHEyyRVREDG SwissProt Entrez-Gene
Orthologous residues
Tyk2 (human): Y1054‑p, Tyk2 (mouse): Y1051‑p, Tyk2 (rat): Y1053‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

Y951-p - VEGFR2 (human)
Modsite: RFRQGKDyVGAIPVD SwissProt Entrez-Gene
Orthologous residues
VEGFR2 (human): Y951‑p, VEGFR2 (mouse): Y949‑p, VEGFR2 (rat): Y947‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase